Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:focus |
thrombosis
hematologic diseases |
| gptkbp:foundedYear |
2003
|
| gptkbp:founder |
gptkb:David_Phillips
gptkb:Charles_Homcy John T. Curnutte Martha S. Hanlon |
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Portola Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Bevyxxa
Andexxa |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
PTLA
|
| gptkbp:website |
https://www.portola.com/
|
| gptkbp:bfsParent |
gptkb:andexanet_alfa
gptkb:betrixaban gptkb:South_San_Francisco,_California,_USA |
| gptkbp:bfsLayer |
7
|